CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims priority to U.S. Provisional Application No. 62/630,122, filed February 13, 2018, which is hereby incorporated by reference in its entirety.

GOVERNMENT FUNDING

This invention was made with government support under All 09713 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Bacterial infectious diseases kill 100,000 persons each year in the US and 11 million persons each year worldwide, representing nearly a fifth of deaths each year worldwide (Heron et al., Final Data for 2006. National Vital Statistics Reports, Vol. 57 (Centers for Disease Control and Prevention, Atlanta GA) and World Health Organization (2008) The Global Burden of Disease: 2004 Update (World Health Organization, Geneva)). In the US, hospital-acquired bacterial infections strike 2 million persons each year, resulting in 90,000 deaths and an estimated $30 billion in medical costs (Klevins et al., (2007) Estimating health care-associated infections and deaths in U.S. hospitals. Public Health Reports, 122, 160-166; Scott, R. (2009) The direct medical costs of healthcare-associated infections in U.S. hospitals and benefits of prevention (Centers for Disease Control and Prevention, Atlanta GA)).

Worldwide, the bacterial infectious disease tuberculosis kills nearly 2 million persons each year. One third of the world's population currently is infected with tuberculosis, and the World Health Organization projects that there will be nearly 1 billion new infections by 2020, 200 million of which will result in serious illness, and 35 million of which will result in death. Bacterial infectious diseases also are potential instruments of biowarfare and bioterrorism.

For six decades, antibiotics have been a bulwark against bacterial infectious diseases. This bulwark is failing due to the appearance of resistant bacterial strains. For all major bacterial pathogens, strains resistant to at least one current antibiotic have arisen. For several bacterial pathogens, including tuberculosis, strains resistant to all current antibiotics have arisen. Bacterial RNA polymerase (RNAP) is a proven target for antibacterial therapy (Darst, S. (2004) Trends Biochem. Sci. 29, 159-162; Chopra, I. (2007) Curr. Opin. Investig. Drugs 8, 600-607; Villain-Guillot, P., Bastide, L., Gualtieri, M. & Leonetti, J. (2007) Drug Discov. Today 12, 200-208; Ho, M., Hudson, B., Das, K., Arnold, E., Ebright, R. (2009) Curr. Opin. Struct. Biol. 19, 715-723; and Srivastava et al. (2011) Curr. Opin. Microbiol. 14, 532-543). The suitability of bacterial RNAP as a target for antibacterial therapy follows from the fact that bacterial RNAP is an essential enzyme (permitting efficacy), the fact that bacterial RNAP subunit sequences are highly conserved (permitting broad-spectrum activity), and the fact that bacterial RNAP-subunit sequences are highly conserved in human RNAP I, RNAP II, and RNAP III (permitting therapeutic selectivity).

The rifamycin antibacterial agents function by binding to and inhibiting bacterial RNAP (Darst, S. (2004) Trends Biochem. Sci. 29, 159-162; Chopra, I. (2007) Curr. Opin. Investig. Drugs 8, 600-607; Villain-Guillot, P., Bastide, L., Gualtieri, M. & Leonetti, J.

(2007) Drug Discov. Today 12, 200-208; and Ho, M., Hudson, B., Das, K., Arnold, E., Ebright, R. (2009) Curr. Opin. Struct. Biol. 19, 715-723). The rifamycins bind to a site on bacterial RNAP adjacent to the RNAP active center and prevent extension of RNA chains beyond a length of 2-3 nt. The rifamycins are in current clinical use in treatment of both Gram-positive and Gram-negative bacterial infections. The rifamycins are of particular importance in treatment of tuberculosis; the rifamycins are first-line anti-tuberculosis agents and are among the few antituberculosis agents able to kill non-replicating tuberculosis bacteria.

The clinical utility of the rifamycin antibacterial agents is threatened by the existence of bacterial strains resistant to rifamycins (Darst, S. (2004) Trends Biochem. Sci. 29, 159-162; Chopra, I. (2007) Curr. Opin. Investig. Drugs 8, 600-607; Villain-Guillot, P., Bastide, L., Gualtieri, M. & Leonetti, J. (2007) Drug Discov. Today 12, 200-208; and Ho, M., Hudson,

B., Das, K., Arnold, E., Ebright, R. (2009) Curr. Opin. Struct. Biol. 19, 715-723).

Resistance to rifamycins typically involves substitution of residues in or immediately adjacent to the rifamycin binding site on bacterial RNAP— i.e., substitutions that directly decrease binding of rifamycins.

In view of the public-health threat posed by rifamycin-resistant and multidrug- resistant bacterial infections, there is an urgent need for new antibacterial agents that (i) inhibit bacterial RNAP (and thus have the same biochemical effects as rifamycins), but that (ii) inhibit bacterial RNAP through binding sites that do not overlap the rifamycin binding site (and thus do not share cross-resistance with rifamycins. A new drug target— the "switch region"— within the structure of bacterial RNAP has been identified (W02007/094799; Mukhopadhyay, J. et al. (2008) Cell. 135, 295-307; see also Belogurov, G. et al. (2009) Nature. 45, 332-335; Ho et al. (2009) Curr. Opin. Struct.

Biol. 19, 715-723; Srivastava et al. (2011) Curr. Opin. Microbiol. 14, 532-543). The switch region is a structural element that mediates conformational changes required for RNAP to bind and retain the DNA template in transcription. The switch region is located at the base of the RNAP active-center cleft and serves as the hinge that mediates opening of the

active-center cleft to permit DNA binding and that mediates closing of the active-center cleft to permit DNA retention. The switch region can serve as a binding site for compounds that inhibit bacterial gene expression and kill bacteria. Since the switch region is highly conserved in bacterial species, compounds that bind to the switch region are active against a broad spectrum of bacterial species. Since the switch region does not overlap the rifamycin binding site, compounds that bind to the switch region are not cross-resistant with rifamycins.

It has been shown that the a-pyrone antibiotic myxopyronin (Myx) functions through interactions with the bacterial RNAP switch region (W02007/094799; Mukhopadhyay, J. et al. (2008) Cell. 135, 295-307; see also Belogurov, G. et al. (2009) Nature . 45, 332-335; Ho et al. (2009) Curr. Opin. Struct. Biol. 19, 715-723; Srivastava et al. (2011) Curr. Opin.

Microbiol. 14, 532-543). Myx binds to the RNAP switch region, traps the RNAP switch region in a single conformational state, and interferes with formation of a catalytically competent transcription initiation complex. Amino acid substitutions within RNAP that confer resistance to Myx occur only within the RNAP switch region. There is no overlap between amino acid substitutions that confer resistance to Myx and amino acid substitutions that confer resistance to rifamycins and, accordingly, there is no cross-resistance between Myx and rifamycins.

A crystal structure of a non-pathogenic bacterial RNAP, Thermus thermophilus RNAP, in complex with Myx has been determined, and homology models of pathogenic bacterial RNAP, including Mycobacterium tuberculosis RNAP and Staphylococcus aureus RNAP, in complex with Myx have been constructed (W02007/094799; Mukhopadhyay, J. et al. (2008) Cell. 135, 295-307; see also Belogurov, G. et al. (2009) Nature . 45, 332-335; Ho et al. (2009) Curr. Opin. Struct. Biol. 19, 715-723; Srivastava et al. (2011) Curr. Opin.

Microbiol. 14, 532-543). The crystal structure and homology models define interactions between RNAP and Myx and can be used to understand the roles of the "west" and "east"

Myx sidechains as well as the Myx a-pyrone core. United States Patent Numbers 9,133,155, 9,187,446, 9,315,495 and 9,592,221 relate to pyronin compounds that are reported to possess antibacterial activity. There remains a need for pyronin antibacterial compounds that possess improved metabolic stability, improved in vivo pharmacokinetics, improved in vitro antibacterial activity, and/or improved in vivo antibacterial efficacy.

SUMMARY OF THE INVENTION

The invention provides new compositions of matter that inhibit bacterial RNA polymerase and inhibit bacterial growth. The compounds are anticipated to have applications in analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial prophylaxis, antibacterial therapy, and drug discovery.

The invention provides new compositions of matter that inhibit bacterial RNA polymerase and inhibit bacterial growth.

Compounds of this invention are structurally related to previously disclosed pyronins with RNA-polymerase-inhibitory and antibacterial activities.

Compounds of this invention differ from previously disclosed pyronins with RNA- polymerase-inhibitory and antibacterial activities by deuteration of the enecarbamate O-alkyl group.

Applicant has discovered— surprisingly— that deuteration of Ob of the enecarbamate O- alkyl group improves metabolic stability, in vivo bioavailbility, in vitro antibacterial efficacy, and in vivo antibacterial efficacy.

Certain compounds of this invention exhibit higher metabolic stabilities than the corresponding non-deuterated pyronins.

Certain compounds of this invention exhibit superior in vivo pharmacokinetics than the corresponding non-deuterated pyronins.

Certain compounds of this invention exhibit superior in vitro antibacterial efficacies than the corresponding non-deuterated pyronins.

Certain compounds of this invention exhibit superior in vivo antibacterial efficacies than the corresponding non-deuterated pyronins.

An object of this invention is to provide antibacterial compounds that possess one or more of the following: 1) improved metabolic stability, 2) in vivo pharmacokinetics, 3) improved in vitro antibacterial efficacy, and 3) improved in vivo antibacterial efficacy. The compounds of the invention have utility as inhibitors of bacterial RNAP.

The salts of the invention also have utility as inhibitors of bacterial growth.

A particular object of this invention is to provide compounds and pharmaceutical compositions that have utility in the treatment of bacterial infection in a mammal.

Accordingly, in one embodiment the invention provides a compound of of formula la, lb, Ic, or Id:

or a salt thereof, wherein W is sulfur, oxygen, or nitrogen;

X, Y, and Z are individually carbon, sulfur, oxygen, or nitrogen, wherein at least two of X, Y, and Z are carbon;

one of R ¹ and R ² is Ci-Cio alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, aryloxy,

heteroaryl oxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, or heteroaryl, wherein any C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, and heteroaryl is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ³ is absent, or is one of H, C ₁ -C ₂ alkyl, or halogen-substituted C ₁ -C ₂ alkyl;

R ⁴ is absent, or is one of H, halogen, C ₁ -C ₂ alkyl, or halogen-substituted C ₁ -C ₂ alkyl;

V, W, X', Y', and Z' are individually carbon or nitrogen; wherein at least three of V,

W, X', Y', and Z' are carbon;

one of R ^1' and R ^2' is C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, aryloxy,

heteroaryloxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, or heteroaryl, wherein any C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, and heteroaryl is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ^3' , R ^4' , and R ^5' are each independently absent, H, halogen, C ₁ -C ₂ alkyl, or halogen- substituted C1-C2 alkyl;

W" is sulfur, oxygen, or nitrogen; U", V", X", Y", and Z" are individually carbon, sulfur, oxygen, or nitrogen, wherein at least three of U", V", X", Y", and Z" are carbon;

one of R ^1" and R ^2" is Ci-Cio alkyl, C ₂ -C io alkenyl, Ci-Cio alkoxy, aryloxy,

heteroaryl oxy, or NR ^a R ^b , wherein any Ci-Cio alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, or heteroaryl, wherein any C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, and heteroaryl is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ^3" is absent or is one of H, C ₁ -C ₂ alkyl, or halogen-substituted C ₁ -C ₂ alkyl;

R ^{4 "} , R ^{5 "} , and R ^6"' are each independently absent, H, halogen, C ₁ -C ₂ alkyl, or halogen- substituted C1-C2 alkyl;

R ⁵ is H or M ⁺ , where M ⁺ is a pharmaceutically acceptable cation;

R ⁶ is H, halogen, or methyl that is optionally substituted with halogen;

R ⁹ is C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl, wherein any C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl is optionally substituted by at least one of halogen, hydroxy, alkoxy, or NR ^a R ^b ;

R ¹⁰ is methyl that is substituted with 1, 2, or 3 deuterium atoms;

one of R ¹² and R ¹³ is hydrogen or C ₁ -C ₄ straight alkyl, and the other of R ¹² and R ¹³ is C ₁ -C ₁₀ straight or branched alkyl, C ₂ -C ₁₂ straight or branched hydroxyalkyl, C ₂ -C ₁₂ straight or branched alkenyl, C ₂ -C ₁₂ straight or branched hydroxyalkenyl, phenyl, C ₇ -C ₁₂ aralkyl, C ₇ - C ₁₂ (aryl)hydroxyalkyl, C ₆ -Ci ₂ heteroaralkyl, C ₆ -Ci ₂ (heteroaryl)hydroxyalkyl, or R ¹² and R ¹³ are taken together with their intervening atom to form a 4-6 membered ring having 0- 1 ring heteroatoms selected from nitrogen, oxygen or sulfur, said ring optionally substituted by one or two Ci-C ₆ alkyl, C ₂ -C ₆ alkenyl or hydroxyalkyl groups, wherein an alkyl, aryl or heteroaryl moiety of R ¹² and R ¹³ optionally is substituted with 1 -3 groups independently selected from halo, -Ci-C ₆ hydroxyalkyl, -C1-C4 alkoxy, -C1-C4 trifluoroalkoxy, -CN, -C1-C4

alkoxycarbonyl, -C1-C4 alkylcarbonyl, -S(Ci-C ₄ alkyl), and -S02(Ci-C ₄ alkyl);

each R ^a is C ₁ -C ₁₀ alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; and each R ^b is H or Ci-Cio alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy.

The invention also provides a compound of formula la, lb, Ic, or Id, or a

pharmaceutically acceptable salt thereof for use in medical treatment.

The invention also provides a compound of formula la, lb, Ic, or Id, or a

pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of a bacterial infection.

The invention also provides a composition comprising a compound of formula la, lb, Ic, or Id, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The invention also provides a composition comprising a salt of formula la’, lb’, Ic’, or Id’ and a pharmaceutically acceptable carrier. In one embodiment the composition is suitable for intravenous administration. In one embodiment the pharmaceutically acceptable carrier is water. In one embodiment the composition is substantially free of organic co- solvents. In one embodiment the composition is substantially free of surfactants.

The invention also provides the use of a compound of the invention as an inhibitor of a bacterial RNA polymerase.

The invention also provides the use of a compound of the invention as an antibacterial agent.

The invention also provides the use of a compound of the invention as a disinfectant, a sterilant, an antispoilant, an antiseptic, or an antiinfective.

The invention also provides the use of a compound of of formula la, lb, Ic, or Id, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for prophylaxis or treatment of a bacterial infection in a mammal.

The invention also provides a method of inhibiting a bacterial RNA polymerase, comprising contacting a bacterial RNA polymerase with a compound of the invention.

The invention also provides a method of treating a bacterial infection in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of of formula la, lb, Ic, or Id, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

The following definitions are used, unless otherwise indicated.

The term“halo” means fluoro, chloro, bromo, or iodo.

The term "alkyl" used alone or as part of a larger moiety, includes both straight and branched chains. For example, Ci-Cio alkyl includes both straight and branched chained alkyl groups having from one to ten carbon atoms. The term alkyl also includes cycloalkyl groups (e.g. cyclopropyl, cyclobutyl, cyclopently, cyclohexyl, cycloheptyl, and cyclooctyl), as well as (cycloalkyl)alkyl groups (e.g. 3-cyclohexylpropyl, cyclopentylmethyl, 2- cyclohexyl ethyl, and 2-cyclopropylethyl).

The term "alkenyl" used alone or as part of a larger moiety, includes an alkyl that has one or more double bonds. For example, C2-C10 alkenyl includes both straight and branched chained groups having from two to ten carbon atoms and one or more (e.g. 1, 2, or 3) double bonds, as well as (cycloalkyl)alkyl groups having one or more double bonds in the cycloalkyl portion or in the alkyl portion of the (cycloalkyl)alkyl.

The term“alkoxy” used alone or as part of a larger moiety is a group alkyl-O-, wherein alkyl has any of the values defined herein.

The term“aryl” denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. For example, aryl can be phenyl, indenyl, or naphthyl.

The term“heteroaryl” encompasses a radical of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (Ci-C ₄ )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms comprising one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X). For example heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N- oxide).

The term“heterocycle” or“heterocyclyl” ring as used herein refers to a ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur. The ring can be saturated, partially unsaturated, or aromatic. The term includes single (e.g., monocyclic) saturated, partially unsaturated, and aromatic rings (e.g., 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. In one embodiment the term includes 5-6 membered saturated, partially unsaturated, and aromatic heterocycles that include 1-5 carbon atoms and 1-4 heteroatoms.

A bond designated =—= herein represents a double bond that can optionally be cis, trans, or a mixture thereof.

A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. The term“stable compounds,” as used herein, refers to compounds which possess stability sufficient to allow for their manufacture and which maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., formulation into therapeutic products, intermediates for use in production of therapeutic compounds, isolatable or storable intermediate compounds, treating a disease or condition responsive to therapeutic agents.

Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure (i.e., the R and S configurations for each asymmetric center). Therefore, single stereochemical isomers, as well as enantiomeric and

diastereomeric mixtures, of the present compounds are within the scope of the invention. Similarly, E- and Z-isomers, or mixtures thereof, of olefins within the structures also are within the scope of the invention.

It is understood by one skilled in the art that this invention also includes any compound claimed that may be enriched at any or all atoms above naturally occurring isotopic ratios with one or more isotopes such as, but not limited to, deuterium ( ² H or D). As a non-limiting example, a -CEE group may be substituted with -CD _3. When a compound is shown or named as containing a specific isotope, it is understood that the compound is enriched in that isotope above the natural abundance of that isotope. In one embodiment the compound may be enriched by at least 2-times the natural abundance of that isotope. In one embodiment the compound may be enriched by at least 10-times the natural abundance of that isotope. In one embodiment the compound may be enriched by at least lOO-times the natural abundance of that isotope. In one embodiment the compound may be enriched by at least 1000-times the natural abundance of that isotope.

Compounds of this invention may exist in tautomeric forms, such as keto-enol tautomers. The depiction of a single tautomer is understood to represent the compound in all of its tautomeric forms.

The term“pharmaceutically acceptable,” as used herein, refers to a component that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A“pharmaceutically acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention.

The term“pharmaceutically acceptable cation” includes sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum and the like. Particularly acceptable cations are the monovalent catins, including sodium, potassium, lithium, and ammonium, and the like. The term pharmaceutically acceptable cation” also includes cations formed by protonation or alkylation of a pharmaceutically acceptable organic nontoxic bases such as primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. For example, the term“pharmaceutically acceptable cation” includes cations formed from unsubstituted or hydroxyl-substituted mono-, di-, or tri-alkylamines,

dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine;

triethylamine; mono-, bis-, or tris-(2-OH-(Ci-C ₆ )-alkylamine), such as N,N-dimethyl-N-(2- hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, and the like.

ANTIBACTERIAL AGENTS

The invention provides new compositions of matter that highly potently inhibit bacterial RNA polymerase and inhibit bacterial growth. Certain compounds of this invention exhibit potencies higher than the potencies of the natural products myxopyronin A and B and of other known analogs of myxopyronin A and B.

Certain embodiments of the invention also provide methods for preparation of a compound according to general structural formula (la), (lb), (Ic), or (Id).

Certain embodiments of the invention also provide an assay for inhibition of a RNA polymerase comprising contacting a bacterial RNA polymerase with a compound according to general structural formula (la), (lb), (Ic), or (Id).

Certain embodiments of the invention also provide an assay for antibacterial activity comprising contacting a bacterial RNA polymerase with a compound according to general structural formula (la), (lb), (Ic), or (Id). Certain embodiments of the invention also provide the use of a compound according to general structural formula (la), (lb), (Ic), or (Id) as an inhibitor of a bacterial RNA polymerase.

Certain embodiments of the invention also provide the use of a compound according to general structural formula (la), (lb), (Ic), or (Id) as an antibacterial agent.

Certain embodiments of the invention also provide the use of a compound according to general structural formula (la), (lb), (Ic), or (Id) as one of a disinfectant, a sterilant, an antispoilant, an antiseptic, or an antiinfective.

In a certain embodiment for a compound of formula la, lb, Ic, or Id:

W is sulfur, oxygen, or nitrogen;

X, Y, and Z are individually carbon, sulfur, oxygen, or nitrogen, wherein at least two of X, Y, and Z are carbon;

one of R ¹ and R ² is Ci-Cio alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, aryloxy,

heteroaryl oxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy, wherein any C ₁ -C ₅ alkyl and C ₁ -C ₅ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ - C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ³ is absent, or is one of H, C1-C2 alkyl, or halogen-substituted C1-C2 alkyl;

R ⁴ is absent, or is one of H, halogen, C1-C2 alkyl, or halogen-substituted C1-C2 alkyl;

V, W, X', Y', and Z' are individually carbon or nitrogen; wherein at least three of V, W, X', Y', and Z' are carbon;

one of R ^1' and R ^2' is C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, aryloxy,

heteroaryloxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy, wherein any C ₁ -C ₅ alkyl and C ₁ -C ₅ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, Ci-Cio alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ - C1 ₀ alkenyl, or C1-C1 ₀ alkoxy, wherein any C1-C1 ₀ alkyl, C2-C1 ₀ alkenyl, or C1-C1 ₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ^3' , R ^4' , and R ^5' are each independently absent, H, halogen, C ₁ -C ₂ alkyl, or halogen- substituted C1-C2 alkyl;

W" is sulfur, oxygen, or nitrogen;

U", V", X", Y", and Z" are individually carbon, sulfur, oxygen, or nitrogen, wherein at least three of U", V", X", Y", and Z" are carbon;

one of R ^1" and R ^2" is C1-C1 ₀ alkyl, C2-C 1 ₀ alkenyl, C1-C1 ₀ alkoxy, aryloxy,

heteroaryl oxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy, wherein any C ₁ -C ₅ alkyl and C ₁ -C ₅ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C2-C1 ₀ alkenyl, or C1-C1 ₀ alkoxy, wherein any C1-C1 ₀ alkyl, C2-C1 ₀ alkenyl, or C1-C1 ₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ^3" is absent or is one of H, C1-C2 alkyl, or halogen-substituted C1-C2 alkyl;

R ^{4 "} , R ^{5 "} , and R ^6" are each independently absent, H, halogen, C1-C2 alkyl, or halogen- substituted C1-C2 alkyl;

R ⁵ is H or M ⁺ , where M ⁺ is a pharmaceutically acceptable cation;

R ⁶ is H, halogen, or methyl that is optionally substituted with halogen;

R ⁹ is C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl, wherein any C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl is optionally substituted by at least one of halogen, hydroxy, alkoxy, or NR ^a R ^b ;

R ¹⁰ is methyl that is substituted with 1, 2, or 3 deuterium atoms;

one of R ¹² and R ¹³ is hydrogen or C ₁ -C ₄ straight alkyl, and the other of R ¹² and R ¹³ is C ₁ -C ₁₀ straight or branched alkyl, C ₂ -C ₁₂ straight or branched hydroxyalkyl, C ₂ -C ₁₂ straight or branched alkenyl, C ₂ -C ₁₂ straight or branched hydroxyalkenyl, phenyl, C ₇ -C ₁₂ aralkyl, C ₇ - C ₁₂ (aryl)hydroxyalkyl, C ₆ -Ci ₂ heteroaralkyl, C ₆ -Ci ₂ (heteroaryl)hydroxyalkyl, or R ¹² and R ¹³ are taken together with their intervening atom to form a 4-6 membered ring having 0-1 ring heteroatoms selected from nitrogen, oxygen or sulfur, said ring optionally substituted by one or two Ci-C ₆ alkyl, C ₂ -C ₆ alkenyl or hydroxyalkyl groups, wherein an alkyl, aryl or heteroaryl moiety of R ¹² and R ¹³ optionally is substituted with 1-3 groups independently selected from halo, -Ci-C ₆ hydroxyalkyl, -C1-C4 alkoxy, -C1-C4 trifluoroalkoxy, -CN, -C1-C4

alkoxycarbonyl, -C1-C4 alkylcarbonyl, -S(Ci-C ₄ alkyl), and -S02(Ci-C ₄ alkyl);

each R ^a is C ₁ -C ₁₀ alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; and

each R ^b is H or C ₁ -C ₁₀ alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy.

In a certain embodiment, the compound of formula la is a compound of la” and the compound of formula Id is a compound of formula Id”.

wherein:

W is sulfur, oxygen, or nitrogen;

X, Y, and Z are individually carbon, or nitrogen, wherein at least two of X, Y, and Z are carbon;

one of R ¹ and R ² is Ci-Cio alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, aryloxy,

heteroaryl oxy, or NR ^a R ^b , wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkoxy, tetrahydrofuranyl, or furanyl, and wherein any aryloxy or heteroaryloxy is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy, aryl, or heteroaryl, wherein any C ₁ -C ₅ alkyl, C ₁ -C ₅ alkoxy, aryl, and heteroaryl is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₅ alkyl, or C ₁ -C ₅ alkoxy; or one of R ¹ and R ² is a 5-6-membered saturated, partially unsaturated, or aromatic heterocycle that is optionally substituted by at least one of halogen, hydroxy, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy; and the other of R ¹ and R ² is absent or is one of H, halogen, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy, wherein any C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, or C ₁ -C ₁₀ alkoxy is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy;

R ³ is absent, or is one of H, C ₁ -C ₂ alkyl, or halogen-substituted C ₁ -C ₂ alkyl;

R ⁴ is absent, or is one of H, halogen, C ₁ -C ₂ alkyl, or halogen-substituted C ₁ -C ₂ alkyl;

R ⁵ is H or M ⁺ , where M ⁺ is a pharmaceutically acceptable cation;

R ⁶ is H, halogen, or methyl that is optionally substituted with halogen;

R ⁹ is C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl, wherein any C ₁ -C ₁₀ alkyl or C ₂ -C ₁₀ alkenyl is optionally substituted by at least one of halogen, hydroxy, alkoxy, or NR ^a R ^b ;

R ¹⁰ is methyl that is substituted with 1, 2, or 3 deuterium atoms;

one of R ¹² and R ¹³ is hydrogen or C ₁ -C ₄ straight alkyl, and the other of R ¹² and R ¹³ is C ₁ -C ₁₀ straight or branched alkyl, C ₂ -C ₁₂ straight or branched hydroxyalkyl, C ₂ -C ₁₂ straight or branched alkenyl, C ₂ -C ₁₂ straight or branched hydroxyalkenyl, phenyl, C ₇ -C ₁₂ aralkyl, C ₇ - C ₁₂ (aryl)hydroxyalkyl, C ₆ -Ci ₂ heteroaralkyl, C ₆ -Ci ₂ (heteroaryl)hydroxyalkyl, or R ¹² and R ¹³ are taken together with their intervening atom to form a 4-6 membered ring having 0- 1 ring heteroatoms selected from nitrogen, oxygen or sulfur, said ring optionally substituted by one or two Ci-C ₆ alkyl, C ₂ -C ₆ alkenyl or hydroxyalkyl groups, wherein an alkyl, aryl or heteroaryl moiety of R ¹² and R ¹³ optionally is substituted with 1 -3 groups independently selected from halo, -Ci-C ₆ hydroxyalkyl, -C1-C4 alkoxy, -C1-C4 trifluoroalkoxy, -CN, -C1-C4

alkoxycarbonyl, -C1-C4 alkylcarbonyl, -S(Ci-C ₄ alkyl), and -S02(Ci-C ₄ alkyl);

each R ^a is C ₁ -C ₁₀ alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy; and

each R ^b is H or C ₁ -C ₁₀ alkyl that is optionally substituted by at least one of halogen, hydroxy, or C ₁ -C ₅ alkoxy.

In a certain embodiment, the invention provides a compound of formula la, or a salt thereof.

In a certain embodiment, the invention provides a compound of formula lb, or a salt thereof.

In a certain embodiment, the invention provides a compound of formula Ic, or a salt thereof. In a certain embodiment, the invention provides a compound of formula Id, or a salt thereof.

In a certain embodiment, R ⁶ is H.

In a certain embodiment, R ⁶ is methyl.

In a certain embodiment, R ⁶ is methyl and the compound, or a salt thereof, is a mixture of the R and S stereoisomers.

In a certain embodiment, R ⁶ is methyl and the compound, or a salt thereof, is predominantly the R stereoisomer, preferably at least 90% of the R isomer.

In a certain embodiment, the compound has formula la’, lb’, Ic’, or Id’:

wherein Y is a pharmaceutically acceptable counter ion.

In a certain embodiment, R ¹⁰ is methyl that is enriched in deuterium by at least 10- times the natural abundance of deuterium.

In a certain embodiment, the compound is selected from

 and

In a certain embodiment, the compound is

In a certain embodiment, the invention provides a composition that is suitable for intravenous administration. In a certain embodiment, the pharmaceutically acceptable carrier is water. In a certain embodiment, the composition is substantially free of co-solvents and surfactants. In a certain embodiment, the composition is substantially free of organic co- solvents.

In a certain embodiment, R ⁵ is not a cation (e.g. a pharmaceutically acceptable cation).

COMPOUND SYNTHESIS

Ene-ester-containing precursors for synthesis of the O-alkyl-deuterated compounds of Formulae Ia-Id can be prepared, for example, as described for synthesis of the corresponding non-O-alkyl-deuterated pyronins in United States Patent Numbers 9,133,155, 9,187,446, 9,315,495 and 9,592,221, as in Scheme 1, and as in the Examples.

Starting from said ene-ester-containing precursors, the O-alkyl-deuterated compounds of Formulae Ia-Id can be prepared, for example, by converting the ene-ester by into an acyl azide, followed by Curtius rearrangement to yield the isocyanate, followed by addition of deuterated methanol, as in Scheme 1 and as in the Examples.

Starting from the resulting O-alkyl-deuterated "free acids" of Formulae Ia-Id in which R ⁵ = OH, the corresponding "salts" of Formulae Ia-Id in which 0 M ⁺ , where M ⁺ is a pharmaceutically acceptable cation, can be prepared by contacting with an aqueous solution at a pH of at least about 9-10, and preferably at least about 11-12, until solids are dissolved, followed by reversed-phase sold-phase extraction or reversed-phase chromatography, for example, as in the Examples.

Scheme 1 : General Scheme for Preparing Compounds

Example 1 : R ¹ =CH ₃ , R ² =CH ₃ , R ³ =H, R ⁴ =F, R ⁵ =CH ₃

Example 2: R ¹ =H, R ² =CH ₃ , R ³ =H, R ⁴ =F, R ⁵ =CH ₃

Example 3: R ¹ =CH ₃ , R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CH ₃

Example 4: R ¹ =CH ₃ , R ² =CH ₃ , R ³ =H, R ⁴ =F, R ⁵ =CD ₃

Example 5: R ¹ =H, R ² =CH ₃ , R ³ =H, R ⁵ =CD ₃

Example 6: R ¹ =H, R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CH ₃

Example 7: R ¹ =CH ₃ , R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CD ₃

Example 8: R ¹ =H, R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CD ₃

Example 10: R ¹ =H, R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CD ₃ , potassium salt

Example 9: R ¹ =H, R ² =H, R ³ =H, R ⁴ =F, R ⁵ =CD _3> sodium salt

Example 14: R ¹ =H, R ² =H, R ³ =CI, R ⁴ =F, R ⁵ =CD ₃

Example 15: R ¹ =H, R ² =H, R ³ =CI, R ⁴ =F, R ⁵ =CD ₃ , sodium salt

Example 16: R ¹ =H, R ² =H, R ³ =H, R ⁴ =Ph, R ⁵ =CD ₃

Example 17: R ¹ =H, R ² =H, R ³ =H, R ⁴ =Ph, R ⁵ =CD ₃ , sodium salt

Example 18: R ¹ =H, R ² =H, R ³ =Br, R ⁴ =F, R ⁵ =CD ₃ Example 19: R ¹ =H, R ² =H, R ³ =Ph, R ⁴ =F, R ⁵ =CD ₃

Example 20: R ¹ =H, R ² =H, R ³ =F, R ⁴ =F, R ⁵ =CD ₃

a = (1 ) LDA (2) 4-bromobutene

b = Methyl crotonate/Hoveyda Grubbs catalyst II

c = 2-(4-fluorophenoxy)-4-methylthiazole-5-carbaldehyde/piperidi ne or 2-(4-fluorophenoxy)thiazole-5- carbaldehyde/piperidine

d = LiOH

e = (1 ) EtOCOCI, DIPEA, NaN ₃

(2) toluene extraction

(3) toluene/MeOH or toluene/d ₄ MeOH reflux

ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS

The compounds of Formulae Ia-Id may be formulated as pharmaceutical

compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration (i.e., orally or parenterally, by

intravenous, intramuscular, topical or subcutaneous routes).

Thus, the present compounds may be systemically administered, e.g., orally, in

combination with a pharmaceutically acceptable vehicle such as an inert diluent or an

assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.

For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful

compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following:

binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like;

a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene

glycol. Various other materials may be present as coatings or to otherwise modify the

physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions. For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

The compound is conveniently formulated in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. In one embodiment, the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

The following illustrate representative preferred pharmaceutical dosage forms, containing a compound of formula la, lb, Ic, or Id, or a pharmaceutically acceptable salt thereof, for therapeutic or prophylactic use in humans:

a) A formulation comprising from about 0.25 mg/ml to about 10 mg/ml of said compound, about 0% to about 10% dim ethyl acetamide, and about 0% to about 10%

Cremophor EL;

b) A formulation comprising from about 0.25 mg/ml to about 10 mg/ml of said compound, about 2% to about 5% dim ethyl acetamide, and about 0% to about 5% Cremophor EL;

c) A formulation comprising from about 0.25 mg/ml to about 10 mg/ml of a pharmaceutically acceptable salt of said compound and about 5% dextrose in about 10 mM sodium phosphate at about pH 7.4; and

d) A formulation comprising from about 0.25 mg/ml to about 10 mg/ml of a pharmaceutically acceptable salt of said compound in phosphate-buffered saline at about pH 7.4; and

e) A formulation comprising from about 0.25 mg/ml to about 10 mg/ml of a pharmaceutically acceptable salt of said compound in about 0 to about 1%

carboxymethylcellulose and about 0 to about 1% Tween 80.

The invention will now be illustrated by the following non-limiting Examples.

EXAMPLES

Example 1 :

Example 1.1 : ethyl 2-(4-fluorophenoxy)-4-methylthiazole-5-carboxylate

4-Fluorophenol (Sigma-Aldrich; 2 g; 17.84 mmol), ethyl 2-bromo-4-methylthiazole-5- carboxylate (Ark Pharm; 4 g; 16 mmol), and cesium carbonate (Sigma-Aldrich; 6.24 g; 19.15 mmol) were thoroughly mixed in 32 ml anhydrous dimethylsulfoxide, and the resulting slurry stirred vigorously 16 h at 45°C. After cooling to 25°C, the reaction mixture was poured into 200 ml water. Organics were extracted with 4x100 ml ether, and the pooled extracts were washed with 50 ml water, washed with 50 ml brine, dried over anhydrous sodium sulfate, filtered, and concentrated to 4.51 g brown solid. NMR showed the desired product, ethyl 2- (4-fluorophenoxy)-4-methylthiazole-5-carboxylate, which was used in the next step without further purification. Yield: 4.51 g (100%). ¹ H NMR (400 MHz, CDCb): d 7.21 (m, 2H), 7.05 (m, 2H), 4.28 (q, 2H),) 2.48 (s, 3H), 1.32 (t, 3H).

Example 1.2: (2-(4-fluorophenoxy)-4-methylthiazol-5-yl)methanol

Ethyl 2-(4-fluorophenoxy)-4-methylthiazole-5-carboxylate (Example 1.1; 4.51 g; 16.03 mmol) was dissolved in 50 ml anhydrous tetrahydrofuran and cooled to -78°C. DIB AH (Sigma- Aldrich; 48 ml 1 M in hexanes; 48 mmol) was added over 15 min, and the reaction mixture was allowed to stir 2 h at -78°C and 0.5 h at 0°C. The reaction was quenched by dropwise addition of 1.5 ml water, dropwise addition of 1.5 ml 15% NaOH, addition of -500 mg anhydrous magnesium sulfate, and addition of 100 ml dichlorom ethane, and then was stirred vigorously 15 min at 25°C. The suspension was filtered, and the retentate was washed with 500 ml dichloromethane and filtered. The pooled filtrates were evaporated, and the product was isolated via silica chromatography ethyl acetate/hexanes gradient) on a

CombiFlash Companion (Teledyne ISCO). Yield: 3 g (78%). ¾ NMR (400 MHz, CDCh): d 7.21 (d, 2H), 7.05 (d, 2H), 4.66 (s, 2H),) 2.48 (s, 3H).

Example 1.3: 2-(4-fluorophenoxy)-4-methylthiazole-5-carbaldehyde

To (2-(4-fluorophenoxy)-4-methylthiazol-5-yl)methanol (Example 1.2; 2.43 g; 10.2 mmol) in 50 ml anhydrous tetrahydrofuran, were added molecular sieves (Sigma- Aldrich; 4 A; 6.4 g) and activated manganese dioxide (Sigma- Aldrich; 9.24 g; 105 mmol), and the reaction mixture was heated for 2.5 h at 45°C. Thin-layer chromatography showed that all starting material was consumed. The reaction mixture was allowed to cool to 25°C and was filtered through a pad of Celite (Sigma-Aldrich). Yield: 2.43g, 100%. 'H NMR (400 MHz, CDCh): d 9.94 (s, 1H), 7.27 (d, 2H), 7.18 (d, 2H), 2.58 (s, 3H).

Example 1.4: 6-(hex-5-en-2-yl)-4-hydroxy-3-propionyl-2H-pyran-2-one

Lithium diisopropylamide (32.5 mmol) was freshly prepared according to the following procedure: Diisopropylamine (Sigma- Aldrich; 4.7 ml; 33.15 mmol) in 30 ml tetrahydrofuran was cooled to -78°C; n-butyl-lithium (Sigma- Aldrich; 13 ml 2.5 M in hexanes; 32.5 mmol) was added drop-wise over 10 min. Stiriring was continued for 20 min at 0°C, followed by re-cooling to -78°C. 6-Ethyl-4-hydroxy-3-propionyl-2H-pyran-2-one (Ark Pharm or prepared according to Panek, et. al. J Org. Chem. 1998, 63, 2401; 2 g; 10.2 mmol) was dissolved in 20 mL tetrahydrofuran-hexamethylphosphoramide (Sigma- Aldrich; 15:5, v/v) and added to the freshly-prepared lithium diisopropylamide drop-wise over 10 minutes. The reaction mixture was stirred for 2 h at -78°C. 4-Bromobutene (Sigma-Aldrich; 1.66 g; 12.3 mmol) was added drop-wise, and the reaction mixture was stirred overnight, allowing the temperature to increase to room temperature. The reaction was quenched with saturated ammonium chloride and extracted with 3-x-30 ml ethyl acetate, and the ethyl acetate extracts were pooled, washed with 30 ml brine, dried over anhydrous sodium sulfate, and evaporated to an oil. The product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a CombiFlash Companion. Yield: 1.86 g (73%). ¾ NMR (400 MHz, CDCh): d 5.86 (s, 1H), 5.70 (m, 1H), 5.00-4.95 (m, 2H), 3.05 (q, 2H), 2.80 (m, 1H), 2.05 (m, 2H), 1.75 (m, 1H), 1.60 (m, 1H), 1.25 (d, 3H), 1.18 (t, 3H).

Example 1.5: methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)hept-2-enoa te

To 6-(hex-5-en-2-yl)-4-hydroxy-3-propionyl-2H-pyran-2-one (Example 1.4; 2.45 g; 9.8 mm) and methyl crotonate (Sigma-Aldrich; 5.2 ml; 49 mmol) in 20 ml anhydrous

dichloromethane, was added Hoveyda-Grubbs Catalyst II (Sigma-Aldrich; 245 mg; 0.392 mmol), and the reaction mixture was heated 5 h at 40°C. The solvent was evaporated, and the product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a CombiFlash Companion. Yield: 1.2 g (40%). ¾ NMR (400 MHz, CDCh):

d 6.90 (m, 1H), 5.90 (s, 1H), 5.82 (d, 2H), 3.70 (s, 3H), 3.10 (q, 2H), 2.60 (m, 1H), 2.20 (m, 2H), 1.90 (m, 1H), 1.70 (m, 1H), 1.25 (d, 3H), 1.18 (t, 3H). Example 1.6: methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 - methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoate

Methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)hept-2-enoa te (Example 1.5; 100 mg; 0.324 mmol) and 2-(4-fluorophenoxy)-4-methylthiazole-5-carbaldehyde (Example 1.3; 156 mg; 0.658 mmol) were mixed in 2 ml isopropanol in a sealed vial, warmed until the solids went into solution, and allowed to cool to 25°C. Piperidine (Sigma-Aldrich; 32 pl; 0.324 mmol) was added, and the reaction mixture was heated 16 h at 70 °C with vigorous stirring. The reaction mixture was evaporated to an oil, re-dissolved in 10 ml

dichloromethane, shaken vigorously with 5 ml 1 M HC1 in a separatory funnel, and re-extracted with 2x10 ml dichloromethane. The combined dichloromethane extracts were washed with 5 ml water and 5 ml brine, dried over anhydrous sodium sulfate, and evaporated to an oil. The product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a CombiFlash Companion to give give 48 mg of a ~l : 1 mixture of the desired product, (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 -methylacryloyl)-4- hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoate, and 4-methyl -2-(piperi din- l-yl)thiazole-5- carbaldehyde (unwanted side product removed in next step). Yield:32 m; 20%. 'H NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.88 (m, 1 H), 5.97 (s, 1 H), 5.81 (d, 1 H), 3.72 (s, 3 H), 2.60 (m, 1 H), 2.38 (s, 3 H), 2.20 (m, 2H), 2.08 (s, 3 H), 1.88 (m,

1 H), 1.66 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 528.56 (MH ⁺ ); found: 527.97. Example 1.7: (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 -methylacryloyl)- 4-hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoic acid

To crude methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 - methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoate (Example 1.6; 48 mg) in 3.2 ml t-butanol and 0.89 ml water, was added 0.84 ml 1M Li OH. The mixture was microwaved (Biotage Initiator, Biotage) 1 h at 60°C. ETpon cooling to 25°C, the reaction mixture was evaporated to dryness, re-dissolved in 10 ml ethyl acetate and 5 ml 0.5 M HC1, adjusted to pH ~ 2, and extracted with 3x10 ml ethyl acetate. The pooled extracts were washed with brine, dried over anhydrous sodium sulfate, and evaporated to an oil. The crude sample was purified via semi-preparative reversed-phase HPLC (25 cm x 10 mm Phenomenx Jupiter Cl 8 column, 300 A, 10 m; A = 1% acetic acid; B = 1% acetic acid in acetonitrile;

gradient = 40% B to 100% B at 30 min; flow rate = 4 ml/min). Yield: 18.6 mg ;40%).

¾ NMR (500 MHz, CDCh): . d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.88 (m, 1 H),

5.97 (s, 1 H), 5.81 (d, 1 H), 2.60 (m, 1 H), 2.38 (s, 3 H), 2.20 (m, 2H), 2.08 (s, 3 H), 1.88 (m,

1 H), 1.66 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 514.56 (MH ⁺ ); found: 514.06. Example 1.8: i) Et ₃ N, CIC(0)OEt

ii) a NaN (excess)

Example 1 was obtained by conversion of (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4- methylthiazol-5-yl)-2-methylacryloyl)-4-hydroxy-2-oxo-2H-pyr an-6-yl)hept-2-enoic acid (Example 1.7) into the acyl azide, followed by Curtius rearrangement under thermal conditions to yield the isocyanate, followed by addition of deuterated methanol.

To (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 -methylacryloyl)-4- hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoic acid (Example 1.7; 31.6 mg, 0.062 mmol) and diisopropylamine (Sigma-Aldrich; 54 mΐ; 0.25 mmol) in anhydrous acetone (7 ml) under argon at 0°C, was added ethyl chloroformate (Sigma-Aldrich; 24 mΐ; 0.25 mmol), and the reaction was stirred 1.5 h at 0°C. Sodium azide (40 mg; 0.62 mmol) in 1.5 ml water was addded, the reaction mixture was allowed to stir 45 min at 0°C, and the reaction was quenched by addition of 10 ml water. The pH of the mixture was adjusted to ~2 by addition of 1 N HCL. Organics were extracted with 3x20 ml ethyl acetate, and the combined extracts were washed with 20 ml brine, dried over anhydrous sodium sulfate, evaporated to an oil, and trace water was removed by azeotropic evaporation of added anhydrous toluene (3x10 ml). The crude azide was further dried 20 min under high vacuum, then re-dissolved in anhydrous toluene (6 ml) and heated for 2 h at 1 l0°C. The reaction mixture was allowed to cool to 80°C, 3 ml anhydrous methanol was added, and heating was continued for 12 h at 80°C. The reaction mixture was allowed to cool to room temperature and then evaporated to dryness.

The crude sample was purified via semi-preparative reversed-phase HPLC (25 cm x 10 mm Phenomenx Jupiter Cl 8 column, 300 A, 10 m; A = 1% acetic acid; B = 1% acetic acid in acetonitrile; gradient = 40% B to 100% B at 30 min; flow rate = 4 ml/min).

Yield: 20 mg (61%). ¾ NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (broad m, 1 H), 3.71 (s, 3 H), 2.62 (m, 1 H), 2.38 (s, 3 H), 2.09 (s, 3 H), 2.05 (m, 2 H), 1.80 (m, 1 H),

1.60 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 543.58 (MH ⁺ ); found: 543.10, 565.08 (M+Na). Example 2:

Example 2.1 : 2-(4-fluorophenoxy)thiazole

4-Fluorophenol (Sigma-Aldrich; 4.8 g; 43 mmol) and potassium carbonate (7.4 g; 54 mmol) were mixed in 20 ml anhydrous DMF, and the resulting slurry was stirred vigorously 0.5 h at l30°C. After allowing the reaction mixture to cool to 80°C, 2-bromothiazole (Sigma- Aldrich; 5.8 g; 36 mmol) in 5 ml DMF was added drop-wise over 5 min, and the reaction mixture was heated 16 h at l30°C. After cooling to 25°C, 50 ml water was added, and the reaction mixture was extracted with 3x50 ml ethyl acetate. The extracts were pooled and washed with 3x25 ml 6% NaOH, 25 ml water, and 25 ml brine, and were dried over anhydrous sodium sulfate and concentrated to a brown oil. The product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a CombiFlash Companion.

Yield: 6.88 g (99%). ¾ NMR (500 MHz, CDCb): d 7.27 (m, 3 H), 7.22 (d, 2 H), 7.10 (d, 2 H)

Example 2.2: 2-(4-fluorophenoxy)thiazole-5-carbaldehyde

Freshly prepared lithium diisopropylamide (53 mmol in 60 ml tetrahydrofuran; see Example 1.2) was cannulated into a solution of 2-(4-fluorophenoxy)thiazole (Example 2.1; 6.88 g; 35.2 mmol) in 60 ml anhydrous tetrahydrofuran at -78°C (dry ice bath) over 5 min. The reaction mixture was stirred 30 min, 5.5 ml anhydrous DMF added drop-wise over 5 min, and stirring was continued for 10 min. The dry ice bath was removed, and the reaction mixture was stirred for 10 min. The reaction was quenched with 50 ml saturated ammonium chloride and extracted with 3x50 ml ethyl acetate, and the pooled organic extracts were dried with brine and anhydrous sodium sulfate and evaporated to a brown solid. The product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a CombiFlash Companion.

Yield: 4.7 g (60%). ¾ NMR (500 MHz, CDCh): d 9.95 (s, 1 H), 8.17 (s, 1 H), 7.27 (d, 2H), 7.18 (d, 2H).

Example 2.3: methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)thiazol-5-yl)-2-methylac ryloyl)-4- hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoate

The compound was prepared from methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6- yl)hept-2-enoate (Example 1.5; 100 mg; 0.325 mmol) and 2-(4-fluorophenoxy)thiazole-5- carbaldehyde (Example 2.2; 72.5 mg; 0.325 mmol) and piperidine (32 mΐ, 0.325

mmol)according to the procedures in Example 1.6. Yield: 51 mg (30%).

¾ NMR (500 MHz, CDCh): d 7.37 (s, 1H), 7.29 (d, 2 H), 7.13 (d, 2 H), 7.03 (s, 1 H), 6.90 (m, 1 H), 5.97 (s, 1 H), 5.81 (d, 1 H), 3.72 (s, 3 H), 2.60 (m, 1 H), 2.20 (m, 2H), 2.14 (s, 3 H), 1.88 (m, 1 H), 1.66 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 514.56 (MH ⁺ ); found: 514.97.

Example 2.4: (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)thiazol-5-yl)-2-methylac ryloyl)-4- hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoic acid

The compound was prepared from methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)thiazol-5-yl)- 2-methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoat e (Example 2.3), according to the procedures in Example 1.7. Yield: 45 mg (91%). ¾ NMR (500 MHz, CDCh): d 7.37 (s, 1H), 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.88 (m, 1 H), 5.97 (s, 1 H), 5.81 (d, 1 H), 2.60 (m, 1 H), 2.20 (m, 2H), 2.08 (s, 3 H), 1.88 (m, 1 H), 1.66 (m, 1 H), 1.25 (d, 3 H)

MS (MALDI): calculated: m/z 500.56 (MH ⁺ ); found: 500.06.

Example 2.5:

The compound was prepared from (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)thiazol-5-yl)-2- methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hept-2-enoic acid (Example 2.4), according to the procedures in Example 1.8. Yield: 16 mg (34%). ¾ NMR (500 MHz, CDCh): d 7.36 (s, 1H), 7.27 (d, 2 H), 7.15 (d, 2 H), 7.02 (s, 1 H), 6.51-6.43 (broad m, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (broad m, 1 H), 3.71 (s, 3 H), 2.62 (m, 1 H), 2.09 (s, 3 H), 2.05 (m, 2 H), 1.80 (m, 1 H), 1.60 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 528.60 (MH ⁺ ); found: 528.10, 540.08 (M+Na). Example 3 :

Example 3.1 : 4-hydroxy-6-(pent-4-en- 1 -yl)-2H-pyran-2-one

The compound was prepared by reacting 4-hydroxy-6-methyl-2H-pyran-2-one

(Sigma-Aldrich) with lithium diisopropylamide (2 mole equivalentsLDA to pyrone), followed by addition of 4-bromobutene, according to the procedures in Example 1.4.

Yield: 3.5 g (97%). ¾ NMR (500 MHz, CDCh): d 5.97 (s, 1H), 5.70 (m, 1H), 5.58 (s, 1H), 5.00-4.95 (m, 2H), 2.42 (t, 2H), 2.02 (m, 2H), 1.85 (m, 2H). MS (API-ESI): calculated: m/z

180.20 (MH ⁺ ); found: 180.91

Example 3.2: 4-hydroxy-6-(pent-4-en-l-yl)-3-propionyl-2H-pyran-2-one

N,N’-Diisopropylcarbodiimide (Sigma-Aldrich; 2.283 ml,; 14.74 mmol), 4-

(dimethylamino)pyridine (Sigma-Aldrich; 139 mg, 1.14 mmol), propionic acid (Sigma- Aldrich; 1.02 ml, 13.61 mmol), and 4-hydroxy-6-(pent-4-en-l-yl)-2H-pyran-2-one (Example 3.1; 2.2 g; 11.34 mmol) were dissolved in 66 ml toluene and heated 5 h at l00°C under argon. ETpon cooling to 25°C, the reaction mixture was filtered, and the filtrate was washed with 50 ml 0.5 M HC1, 25 ml water, and 25 ml brine, and dried over anhydrous sodium sulfate. The product was isolated via silica chromatography (ethyl acetate/hexanes gradient) on a

CombiFlash Companion. Yield: 1.86 g (65%). ¾ NMR (500 MHz, CDCh): d 5.96 (s, 1H), 5.80 (m, 1H), 5.05-4.95 (m, 2H), 3.05 (q, 2H), 2.50 (t, 2H), 2.10 (m, 2H), 1.80 (m, 2H),

1.18 (t, 3H). Example 3.3: methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)hex-2-enoat e

O OH i Mvieemthyyil c crrooitoonnaaitee

Hoveda Grubbs

The compound was prepared from 4-hydroxy-6-(pent-4-en-l-yl)-3-propionyl-2H-pyran-2- one (Example 3.2, according to the procedures in Example 1.5. Yield: 0.9 g (30 %).

¾ NMR (500 MHz, CDCl ₃ ): ¹ H NMR (400 MHz, CDCb): d 6.90 (m, 1H), 5.90 (s, 1H), 5.82 (d, 2H), 3.70 (s, 3H), 3.10 (q, 2H), 2.50 (t, 2H), 2.10 (m, 2H), 1.80 (m, 2H), 1.18 (t, 3H).

Example 3.4: methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 - methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hex-2-enoate

The compound was prepared from methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6- yl)hex-2-enoate (Example 3.3) and 2-(4-fluorophenoxy)-4-methylthiazole-5-carbaldehyde (Example 1.3), according to the procedures in Example 1.6. Yield: 130 mg (15%).

¾ NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.88 (m, 1 H), 5.97 (s, 1 H), 5.81 (d, 1 H), 3.72 (s, 3 H), 2.50 (t, 2H), 2.38 (s, 3 H), 2.25 (m, 2H), 2.08 (s, 3 H), 1.80 (m, 2H). MS (MALDI): calculated: m/z 514.56 (MH ⁺ ); found: 514.97.

Example 3.5: (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5-yl)-2 -methylacryloyl)- 4-hydroxy-2-oxo-2H-pyran-6-yl)hex-2-enoic acid

The compound was prepared from methyl (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4- methylthiazol-5-yl)-2-methylacryloyl)-4-hydroxy-2-oxo-2H-pyr an-6-yl)hex-2-enoate (Example 3.4), according to the procedures in Example 1.7. Yield:78 mg (61%).

¾ NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.88 (m, 1 H), 5.97 (s, 1 H), 5.81 (d, 1 H), 2.50 (t, 2H), 2.38 (s, 3 H), 2.25 (m, 2H), 2.08 (s, 3 H), 1.80 (m, 2H). MS (MALDI): calculated: m/z 500.56 (MH ⁺ ); found: 500.97.

Example 3.6:

The compound was prepared from (E)-6-(3-((E)-3-(2-(4-fluorophenoxy)-4-methylthiazol-5- yl)-2-methylacryloyl)-4-hydroxy-2-oxo-2H-pyran-6-yl)hex-2-en oic acid (Example 3.5), according to the procedures in Example 1.8. Yield: 35 mg (42%). ¾ NMR (500 MHz, CDCh) d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 3.71 (s, 3 H), 2.51 (t, 2 H), 2.38 (s, 3 H), 2.31 (m, 2 H), 2.08 (s, 3 H), 1.88 (m, 2 H). MS (MALDI): calculated: m/z 529.55 (MH ⁺ ); found:

529.10.

Example 4:

The title compound was prepared as described for Example 1, but using deuterated methanol (methanol-d4, 99.8 atom % D; Sigma-Aldrich) in place of methanol in the last step of the synthesis. Deuterated methanol was recovered for future use by distillation. Yield: 3 mg (31%) ¾ NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.62 (m, 1 H), 2.38 (s, 3 H), 2.09 (s, 3 H), 2.05 (m, 2 H), 1.80 (m, 1 H), 1.60 (m, 1 H), 1.25 (d, 3 H) MS

(MALDI): calculated: m/z 547.8 (MH ⁺ ); found: 546.15, 568.13 (M+Na).

Example 5:

The title compound was prepared as described for Example 2, but using deuterated methanol (methanol-d4, 99.8 atom % D; Sigma-Aldrich) in place of methanol in the last step of the synthesis. Deuterated methanol was recovered for future use by distillation

Yield: 230 mg (49%). ¾ NMR (500 MHz, CDCh): d 7.36 (s, 1H), 7.27 (d, 2 H), 7.15 (d,

2 H), 7.02 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (broad m, 1 H), 2.51 (t, 1 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.80 (m, 1 H), 1.60 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 532.57 (MH ⁺ ); found: 532.26. Example 6:

The title compound was prepared as described for Example 2, but using methyl (E)-6-(4- hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)hex-2-enoate (Example 3.3) in place of methyl (E)-6-(4-hydroxy-2-oxo-3-propionyl-2H-pyran-6-yl)hept-2-enoa te. Yield: 22 mg (44%). ¾ NMR (500 MHz, CDCh): d 7.36 (s, 1H), 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51- 6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 3.71 (s, 3 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 515.55 (MH ⁺ ); found: 515.10. Example 7:

The title compound was prepared as described for Example 3, but using deuterated methanol (methanol-d4, 99.8atom % D; Sigma- Aldrich) in place of methanol in the last step of the synthesis. Deuterated methanol was recovered for future use by distillation. Yield: 5.2 mg (71%). ¾ NMR (500 MHz, CDCh): d 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.38 (s, 3 H), 2.32 (m, 2 H), 2.08 (s, 3 H), 1.80 (m, 2 H). MS (MALDI): calculated: m/z 532.57 (MH ⁺ ); found: 532.10.

Example 8:

The title compound was prepared as described for Example 6, but using deuterated methanol (methanol-d4, 99.8atom % D; Sigma- Aldrich) in place of methanol in the last step of the synthesis. Deuterated methanol was recovered for future use by distillation. Yield: 241 mg (48 %). ¾ NMR (500 MHz, CDCh): d 7.36 (s, 1H), 7.27 (d, 2 H), 7.15 (d, 2 H), 7.11 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 518.54 (MH ⁺ ); found: 518.17 Example 9:

Example 7 (241 mg, 0.466 mmol) was suspended in 160 ml 50 mM sodium carbonate, and the suspension was stirred 3 h at 25°C until all solids dissolved. Aliquots (32 ml each) of the resulting solution were applied to 10 g HF Mega BE-C18 reversed-phase cartridges (Agilent; prepared for use by one cycle of filling to rim with acetonitrile and draining and two cycles of filling to rim with water and draining), washed with 2x50 ml degassed water, and eluted with 5x20 ml 50% methanol, monitoring elution by monitoring yellow color. Pooled factions containing APY281 (first two 50% methanol fractions) were evaporated to yield a yellow crystalline solid. Yield: 210 mg (84%). ¾ NMR (500 MHz, CD ₃ OD): d 7.44 (s, 1H), 7.42 (s, 1H), 7.37 (d, 2 H), 7.23 (d, 2 H), 6.43 (d, 1 H), 5.71 (s, 1 H), 5.10 (m, 1 H),2.42 (t, 2 H), 2.13 (m, 2 H), 2.06 (s, 3 H), 1.70 (m, 2 H). MS (MALDI): calculated: m/z 540.54 (M+Na ⁺ ); found: 540.17.

Example 10

(±)Myxopyronin B was prepared as described in ETnited States Patent Number 9, 133, 155. Example 11 :

The title compound was prepared as in ETnited States Patent Number 9, 187,446.

Example 12:

The title compound was prepared as described for (±)myxopyronin B in United States Patent Number 9, 133,155, but using deuterated methanol (methanol-d4, 99.8 atom % D; Sigma- Aldrich) in place of methanol in the last step of the synthesis. MS (MALDI): calculated: m/z 434.20 (MH ⁺ ); found: 435.21

Example 13 :

The title compound was prepared as described for PY62 in United States Patent Number 9, 187,446, but using deuterated methanol (methanol -d4, 99.8 atom % D; Sigma- Aldrich) in place of methanol in the last step of the synthesis. Yield: 2.2 mg (30%). ¾ NMR (500 MHz, CDCh): d 6.82 (d, 1H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.96 (s, 1 H), 4.99-4.88 (m, 1 H), 2.60 (m, 1 H), 2.40 (t, 2 H), 2.25 (m, 2 H),2.0l (s, 3 H), 1.86 (s, 3 H), 1.80 (m, 1 H), 1.60 (m, 1 H), 1.25 (d, 3 H). MS (MALDI): calculated: m/z 475.20 (MH ⁺ ); found: 475.13.

Example 14

The title compound was prepared as described for Example 8, but using 3-chloro-4- fluorophenol (Sigma- Aldrich) in place of 4-fluorophenol (see Example 1.1). Yield (last reaction step): 47 mg (45%). ¾ NMR (500 MHz, CDCh): d 7.42 (br s, 1H), 7.34 (s, 1 H), 7.15 (m, 2 H), 7.02 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 552.98 (MH ⁺ ); found: 551.99, 553.95.

Example 15:

The compound of Example 14 (26 mg; 47 pmol) was suspended in 15 ml 50 mM sodium carbonate and stirred for 16 h at 25°C. The resulting solution was applied to a 10 g HF Mega BE-C18 reversed-phase cartridge (Agilent; prepared for use by one cycle of filling to rim with acetonitrile and draining and two cycles of filling to rim with water and draining), washed with 2x50 ml degassed water, and eluted with 1x10 mL 50% methanol, 1x10 mL 75% methanol, and 1x10 mL 80% methanol, monitoring elution by monitoring yellow color. Pooled factions containing the title compound (first two fractions) were evaporated to yield a yellow crystalline solid. Yield: 18 mg (67%).

Example 16:

The title compound was prepared as described for Example 8, but using 4-phenylphenol (Sigma- Aldrich) in place of 4-fluorophenol (see Example 1.1). Yield (last reaction step): 82 mg (70%). ¾ NMR (500 MHz, CDCh): d 7.66-7.25 (m, 9 H), 7.34 (s, 1 H), 7.05 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 575.65 (MH ⁺ ); found: 576.01, 597.99 (MNa ⁺ ). Example 17:

The compound of Example 15 (20 mg; 35 pmol) was suspended in 12 ml 50 mM sodium carbonate and stirred for 16 h at 25°C. The resulting solution was applied to a 10 g HF Mega BE-C18 reversed-phase cartridge (Agilent; prepared for use by one cycle of filling to rim with acetonitrile and draining and two cycles of filling to rim with water and draining), washed with 2x50 ml degassed water, and eluted with 1x10 mL 50% methanol, 1x10 mL 75% methanol, and 1x10 mL 80% methanol, monitoring elution by monitoring yellow color. Pooled factions containing the title compound (last two fractions) were evaporated to yield a yellow crystalline solid. Yield: 12 mg (58%).

Example 18:

The title compound was prepared as described for Example 8, but using 3-bromo-4- fluorophenol (Sigma- Aldrich) in place of 4-fluorophenol (see Example 1.1). Yield (last reaction step): 20.7 mg (65%). ¾ NMR (500 MHz, CDCh): d 7.58 (br s, 1 H), 7.35 (s, 1 H), 7.26 (m, 1 H), 7.20 (m, 1 H), 7.01 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 595.17 (MH ⁺ ); found: 593.93, 595.93, 615.91, 617.91. Example 19:

The title compound was prepared from the compound of Example 18 through a Suzuki - Miyaura cross-coupling transformation with phenylboronic acid., as in the following scheme:

A suspension of the compound of Example 18 (80 mg; 168 mchoΐ), phenylboronic acid (41 mg; 336 mchoΐ; Sigma-Aldrich), potassium carbonate (70 mg; 504 mchoΐ), palladium acetate (1 mg; 3.36 pmol; Sigma-Aldrich), and RuPhos (3.1 mg; 6.72 pmol; Sigma-Aldrich) in 5 ml toluene:water (9: 1) was heated 16 h at l00°C in a sealed vial. The reaction was allowed to room temperature, was quenched with 3 ml water, and was extracted with 3x5 ml ethyl acetate. The ethyl acetate extracts were pooled, filtered, and evaporated to an oily residue, the oily residue was re-suspended in 5 ml water pre-adjusted to pH 3 (with 1 M HC1), and the suspension was re-extracted with 3x5 mL ethyl acetate. The resulting extracts were pooled, dried with brine and anhydrous sodium sulfate, evaporated, and purified by use of chromatography on silica (12 g). Fractions containing the the product were pooled to yield 16 mg of crude product, which was further purified by use of semi-preparative reversed- phase HPLC (25 cm x 10 mm Phenomenex Jupiter Cl 8 column, 300 A, 10 m; A = 1% acetic acid; B = 1% acetic acid in acetonitrile; gradient = 40% B to 100% B at 25 min; flow rate = 4 ml/min). Yield: 4 mg (4%). ¾ NMR (500 MHz, CDCh): d 7.57 (s, 1 H), 7.55 (s, 1 H), 7.58 (m, 2 H), 7.40 (m, 3 H), 7.38 (m, 2 H), 7.01 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H). MS (MALDI): calculated: m/z 594.64 (MH ⁺ ); found: 594.18.

Example 20:

The title compound was prepared as described for Example 8, but using 3,4-difluorophenol (VWR) in place of 4-fluorophenol, and using methyl 2-bromothiazole-5-carboxylate (Frontier Scientific) in place of ethyl 2-bromo-4-thiazole-5-carboxylate (see Example 1.1). Yield (last reaction step): 19.8 mg (51%). ¾ NMR (500 MHz, CDCh): d 7.34 (s, 1 H), 7.23 (s, 1 H), 7.21 (m, 1 H), 7.19 (m, 1 H), 7.01 (s, 1 H), 6.51-6.43 (broad t, 1 H), 6.25-6.17 (broad d, 1 H), 5.97 (s, 1 H), 4.99-4.88 (m, 1 H), 2.51 (t, 2 H), 2.13 (s, 3 H), 2.05 (m, 2 H), 1.75 (m, 2 H).

MS (MALDI): calculated: m/z 536.53 (MH ⁺ ); found: 536.03, 558.08 (MNa ⁺ ).

Example 21. Assay of metabolic stability.

Test compounds were incubated with mouse liver microsomes (CD-l; male and female pooled; 1 mg/ml) or human liver microsomes (male; 1 mg/ml) in 50 mM potassium phosphate, pH 7.4, and and 1 mM NADPH at 37°C. Aliquots were removed at 0, 15, 30, 60, 90 and 120 min, and amounts of test compounds remaining were determined by

LC-MS/MS. Half lives (t0.5) were calculated as t0.5 = -0.693/k, where k is the slope of the linear regression of the natural logarithms of percentages of test compounds remaining vs. time. Data for representative compounds are shown in Table 1. Example 22. Assay of in vivo pharmacokinetics.

Test compounds (2.5 mg/kg; 0.1 ml of 0.625 mg/ml solution in 5% dimethylacetamide and 4% Cremophor EL in 100 mM sodium phosphate, pH 7.4) were administered to mice (CD-l; 0.024-0.26 kg; n = 3) by intravenous injection into a tail vein at t = 0 h. Blood samples were collected by tail-vein bleed (CB 300 K2E tubes; Sarstedt) at t = 0.02, 0.05, 1, 3, 5, and 8 h, and plasma concentrations of test compounds were determined by LC-MS/MS. Data for representative compounds are shown in Table 2.

Example 23. Assay of inhibition of bacterial RNA polymerase.

Fluorescence-detected RNA polymerase assays with E. coli RNA polymerase were performed by a modification of the procedure of Kuhlman et ak, 2004 [Kuhlman, P., Duff, H. & Galant, A. (2004) A fluorescence-based assay for multisubunit DNA-dependent RNA polymerases. Anal. Biochem. 324, 183-190] Reaction mixtures contained (20 mΐ): 0-100 nM test compound, 75 nM E. coli RNA polymerase s ⁷⁰ holoenzyme, 20 nM 384 bp DNA fragment containing the bacteriophage T4 N25 promoter, 100 mM ATP, 100 mM GTP, 100 mM UTP, 100 mM CTP, 50 mM Tris-HCl, pH 8.0, 100 mM KC1, 10 mM MgCh, 1 mM DTT, 10 pg/ml bovine serum albumin, and 5.5% glycerol. Reaction components other than DNA and NTPs were pre-incubated for 10 min at 37°C. Reactions were carried out by addition of DNA and incubation for 5 min at 37°C, followed by addition of NTPs and incubation for 60 min at 37°C. DNA was removed by addition of 1 mΐ 5 mM CaCh and 2 El DNasel (Ambion, Inc.), followed by incubation for 90 min at 37°C. RNA was quantified by addition of 100 mΐ RiboGreen RNA Quantitation Reagent (Invitrogen, Inc.; 1 :500 dilution in Tris-HCl, pH 8.0, 1 mM EDTA), followed by incubation for 10 min at 25 °C, followed by measurement of fluorescence intensity [excitation wavelength = 485 nm and emission wavelength = 535 nm; QuantaMaster QM1 spectrofluorometer (PTI, Inc.)]. IC50 is defined as the concentration of inhibitor resulting in 50% inhibition of RNA polymerase activity. Data for representative compounds are shown in Table 3.

Example 24. Assay of inhibition of bacterial growth in culture.

Example 24.1. Assay of inhibition of growth of Staphylococcus aureus.

Minimum inhibitory concentrations (MICs) for Staphylococcus aureus ATCC l2600were quantified using spiral gradient endpoint assays, essentially as described [Wallace, A. and Corkill, J. (1989) Application of the spiral plating method to study antimicrobial action. J. Microbiol. Meths. 10, 303-310; Paton, J., Holt, A., and Bywater, M. (1990) Measurement of MICs of antibacterial agents by spiral gradient endpoint compared with conventional dilution methods. Int. J. Exp. Clin. Chemother. 3, 31-38; Schalkowsky S. (1994) Measures of susceptibility from a spiral gradient of drug concentrations. Adv. Exp. Med. Biol. 349, 107- 120] Assays employed exponential -gradient plates containing 150 mm x 4 mm Mueller- Hinton II cation-adjusted agar and 0.4-100 pg/ml of test compound. Plates were prepared using an Autoplate 4000 spiral plater (Spiral Biotech, Inc.). Saturated overnight cultures were swabbed radially onto plates, and plates were incubated for 16 h at 37°C. For each culture, the streak length was measured using a clear plastic template (Spiral Biotech, Inc.), the test-compound concentration at the streak endpoint was calculated using the program SGE (Spiral Biotech, Inc.), and the MIC was defined as the calculated test-compound concentration at the streak endpoint.

Example 24.2. Assay of inhibition of growth of Mycobacterium tuberculosis.

MICs for Mycobacterium tuberculosis H37Rv were quantified using microplate Alamar Blue assays as described [Collins, L. & Franzblau, S. (1997) Microplate Alamar Blue assay versus B ACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41, 1004-1009]

Data for representative compounds from the assay of Example 24 are shown in Table 4.

Example 25. Assay of antibacterial efficacy in mouse model of Staphylococcus aureus systemic infection ("peritonitis model").

Female Swiss Webster mice (0.18-0.22 kg) were experimentally infected by intraperitoneal administration of 1 x 10 ⁷ colony forming units of methicillin-resistant Staphylococcus aureus (MRSA) strain BAA-1707 (ETSA-400, MW2) in 5% hog gastric mucin. Test compounds in vehicle (5% dextrose in 10 mM sodium phosphate, pH 7.4, for Example 9; 5%

dimethylacetamide and 4% Cremophor EL in 100 mM sodium phosphate, pH 7.4, for other compounds), positive control in vehicle (linezolid at 12.5 mg/kg), and negative control (vehicle only), were administered by intravenous injection into a tail vein (200 mΐ) 0 h post-infection to provide single intravenous doses of 1.56, 3.125, 6.25, 12.5, 25, and 50 mg/kg or by oral gavage (400 mΐ) 1 h pre-infection to provide single oral doses of 3.125, 6.25, 12.5, 25, 50, and 100 mg/kg. Survival was monitored for 72 h post-infection. Identities of test salts and controls were blinded from personnel performing injections and monitoring survival. The effective dose 50 (ED 50) was defined as the test-compound dose resulting in 50% survival at 72 h (calculated using the probit method).

Data from the assay of Example 25 are provided in Tables 5 and 6.

Example 26. Assay of antibacterial efficacy in mouse model of Staphylococcus aureus lung infection ("neutropenic pneumonia model").

Female Swiss Webster mice (0.18-0.20 kg) were rendered immunosuppressed by oral gavage for 4 days with cyclophosphamide and were infected by intranasal administration of 1 x 10 ⁸ colony forming units of methicillin-resistant Staphylococcus aureus (MRSA) strain BAA- 1707 (USA-400, MW2). Test compounds in vehicle (5% dextrose in 10 mM sodium phosphate, pH 8.25), positive control in vehicle (vancomycin at 100 mg/kg), and negative control (vehicle only), were administered by intravenous injection into a tail vein (200 mΐ) 1 h post-infection to provide single intravenous doses of 25, 50, amd 100 mg/kg or by oral gavage (200 mΐ) 1 h post-infection to provide oral doses of 100, 200, and 400 mg/kg. Mice were euthanized and lungs were harvested and homogenized 24 h post-infection; and viable bacteria were quantified. The effective dose (ED(2log)) was defined as the minimum test-compound dose resulting in >2 log reduction in bacterial burden.

Data from the assay of Example 26 are provided in Tables 7 and 8.

Example 27. Assay of antibacterial efficacy in mouse model of Staphylococcus aureus dermal infection ("dermal-infection model").

Female BALB/c mice (0.18-0.20 kg) were experimentally infected by topical administration under isfluurane anesthesia of 1 x 10 ⁷ colony forming units of methicillin-resistant

Staphylococcus aureus (MRSA) strain BAA-1707 (USA-400, MW2) to a 20 mmx 20 mm dorsal surface prepared by depiliation (24 h pre-infection; isoflurane anesthesia) and removal of epidermis by tape stripping (immediately pre-infection; isoflurane anesthesia; seven applications and removals of 3M Nexcare surgical tape). Test compounds in vehicle (5% dextrose in 10 mM sodium phosphate, pH 8.25), positive control in vehicle (linezolid at 12.5 mg/kg), and negative control (vehicle only), were administered by intravenous injection into a tail vein (200 mΐ) 0 h post-infection to provide single intravenous doses of 12.5, 25, 50, and 100 mg/kg. Mice were euthanized and a 10 mm x 10 mm skin segment was harvested and homogenized 24 h post-infection; and viable bacteria were quantified. Identities of test salts and controls were blinded from personnel performing injections and quantifying bacteria. The effective dose (ED(2log)) was defined as the minimum test-compound dose resulting in >2 log reduction in bacterial burden.

Data from the assay of Example 27 are provided in Table 9. Example 28. Assay of antibacterial efficacy in mouse model of Mycobacterium tuberculosis aerosol acute infection (" Mtb acute infection model").

Female Balb/c mice (6-8 weeks old) were infected by aerosol administration of 50-100 colony forming units of Mycobacterium tuberculosis Erdman. Test compounds in vehicle (5% dextrose in 10 mM sodium phosphate, pH 8.25), positive control in vehicle (rifampi at 10 and 20 mg/kg), and negative control (vehicle only), were administered by oral gavage

(200 mΐ) starting 7 days post-infection and continuing for 12 days to provide 12 daily oral doses of 100 and 200 mg/kg. Mice were euthanized and lungs and spleens were harvested and homogenized 21 days post-infection; and viable bacteria were quantified. The effective dose (ED(2log)) was defined as the minimum test-compound dose resulting in >2 log reduction in bacterial burden.

Data from the assay of Example 28 are provided in Table 10.

Screening data for representative deuterated compounds of the invention and for corresponding undeuterated compounds are presented in Tables 1-5:

Table 1. Metabolic stability.

Table 2. Pharmacokinetics in mice (intravenous administration).

Table 3. Inhibition of bacterial RNA polymerase

Table 4. Inhibition of bacterial growth

Table 5. Antibacterial efficacy in mice: methicillin-resistant Staphylococcus aureus (MRSA) peritonitis, intravenous administration of test compound (single dose)

Table 6. Antibacterial efficacy in mice: methicillin-resistant

Staphylococcus aureus (MRSA) peritonitis, oral administration of test compound (single dose)

Table 7. Antibacterial efficacy in mice: methicillin-resistant

Staphylococcus aureus (MRSA) lung infection, intravenous administration of test compound (single dose)

Table 8. Antibacterial efficacy in mice: methicillin-resistant

Staphylococcus aureus (MRSA) lung infection, oral administration of test compound (single dose)

Table 9. Antibacterial efficacy in mice: methicillin-resistant

Staphylococcus aureus (MRSA) dermal infection, intravenous administration of test compound (single dose)

Table 10. Antibacterial efficacy in mice: methicillin-resistant

Mycobacterium tuberculosis aerosol acute infection, oral administration of test compound (12 daily doses)

The data in Table 1 show that certain deuterated compounds of this invention

(compounds with underlined data) exhibit higher metabolic half-lives than the corresponding undeuterated compounds.

The data in Table 2 show that certain deuterated compounds of this invention

(compounds with underlined data) exhibit higher plasma half-lives upon intravenous administration to mice than the corresponding undeuterated compounds.

The data in Table 3 show that certain deuterated compounds of this invention

(compounds with underlined data) exhibit higher in vitro RNA polymerase inhibitory potencies than the corresponding undeuterated compounds.

The data in Table 4 show that certain deuterated compounds of this invention

(compounds with underlined data) exhibit higher in vitro antibacterial potencies than the corresponding undeuterated compounds.

The data in Table 5 show that certain deuterated compounds of this invention

(compounds with underlined data) exhibit higher in vivo antibacterial potencies than the corresponding undeuterated compounds.

The data in Tables 5-6 further show that certain compounds of this invention potently treat infection and prevent death in a mammal. Table 5 presents data for survival from experiments with mice with systemic infections of methicillin-resistant Staphylococcus aureus (MRSA) and compounds administered intravenously. Table 6 presents data for survival from experiments with mice with systemic infections of methicillin- resistant Staphylococcus aureus (MRSA) and a compound administered intravenously or orally.

The data in Tables 7-10 indicate that certain compounds of this invention potently treat infections and reduce bacterial burdens in a mammal. Tables 7 and 8 presents data for reductions in plasma bacterial burdens from experiments with mice with lung infections of methicillin-resistant Staphylococcus aureus (MRSA) and a compound administered intravenously or orally. Table 9 presents data for reductions in bacterial burdens from experiments with mice with dermal infections of methicillin-resistant Staphylococcus aureus (MRSA) and a compound administered intravenously. Table 10 presents data for reductions in bacterial burdens from experiments with mice with aerosol acute infections of Mycobacterium tuberculosis and a compound administered orally.

The data in Tables 5-10 further indicate that certain compounds of this invention can be formulated in aqueous vehicles and administered to mammals intravenously at doses up to at least 100 mg/kg or orally at doses up to at least 400 mg/kg,